A Prospective, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-center, 52-week Trial to Assess the Efficacy and Safety of Adjunct Mycophenolate Mofetil (MMF) to Achieve Remission With Reduced Corticosteroid in Subjects With Pemphigus Vulgaris

Trial Profile

A Prospective, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-center, 52-week Trial to Assess the Efficacy and Safety of Adjunct Mycophenolate Mofetil (MMF) to Achieve Remission With Reduced Corticosteroid in Subjects With Pemphigus Vulgaris

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2014

At a glance

  • Drugs Mycophenolate mofetil (Primary)
  • Indications Pemphigus vulgaris
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 02 Apr 2014 New trial record
    • 02 Apr 2014 New trial record
    • 21 Jun 2011
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top